{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:35:45Z","timestamp":1791750945764,"version":"4.3.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Some patients have poor response to adult-onset Still disease (AOSD) traditional treatment, which easily recurs during the reduction of prednisone. We observed the efficacy and safety of tocilizumab combined with methotrexate (MTX) in the treatment of refractory AOSD, and to explore the possibility of reducing the dosage of tocilizumab after disease control.<\/jats:p>\n            <jats:p>A total of 28 refractory AOSD cases who had an inadequate response to corticosteroids combined with at least 1 traditional immunosuppressive agent, and even large-dose prednisone could not relieve their conditions after recurrence, were selected in this study. They were treated with tocilizumab (intravenous 8\u200amg\/kg) combined with MTX (oral 12.5\u200amg once a week). In detail, tocilizumab was firstly given every 4 weeks and after 6-month remission, it was then given every 8 weeks. Some items including body temperature, skin rash, joint swelling and pain, hepatosplenomegaly, blood routine, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum ferritin, and dosage of prednisone were observed before treatment as well as 2, 4, 8, 12, 24, 36, and 48 weeks after treatment. The adverse reactions occurring during the treatment were recorded.<\/jats:p>\n            <jats:p>The body temperature was normal, the skin rash as well as joint swelling and pain disappeared, and laboratory indexes including CRP, ESR, white blood cell, neutrophilic granulocyte, platelet, hemoglobin, and ferritin were significantly improved after 8-week treatment (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). The clinical symptoms and laboratory indexes above mentioned were continuously improved 12, 24, 36, and 48 weeks after treatment. The mean dosage of prednisone was reduced from 71.4\u200a\u00b1\u200a20.7\u200amg\/day to 55.0\u200a\u00b1\u200a11.1\u200amg\/day after 2-week treatment, and to 3.3\u200a\u00b1\u200a2.1\u200amg\/day after 48-week treatment (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). Prednisone was discontinued in 5 cases after 36-week treatment and in 7 cases after 48-week treatment. No serious adverse reactions occurred during the treatment.<\/jats:p>\n            <jats:p>Tocilizumab can rapidly and markedly improve the clinical symptoms and laboratory indexes and contribute to reduction and discontinuation of prednisone in refractory AOSD. The patients\u2019 conditions are stable after reduction or discontinuation of prednisone and the tocilizumab possesses good safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016682","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:40:51Z","timestamp":1565224851000},"page":"e16682","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate"],"prefix":"10.1097","volume":"98","author":[{"given":"Chun-yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250722","first-page":"879020","article-title":"Adult-onset Still's disease: from pathophysiology to targeted therapies","volume":"2012","author":"Mavragani","year":"2012","journal-title":"Int J Inflam"},{"key":"R2-20250722","first-page":"156890","article-title":"IL-18 serum level in adult onset Still's disease: a marker of disease activity","volume":"2012","author":"Colafrancesco","year":"2012","journal-title":"Int J Inflam"},{"key":"R3-20250722","doi-asserted-by":"crossref","first-page":"R616","DOI":"10.1186\/ar1721","article-title":"Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia","volume":"7","author":"Kirino","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R4-20250722","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2032s disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"key":"R5-20250722","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40267-018-0572-5","article-title":"Anakinra in Still's disease: a profile of its use","volume":"34","author":"Katherine","year":"2018","journal-title":"Drugs Ther Perspect"},{"key":"R6-20250722","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R7-20250722","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.rdc.2004.01.008","article-title":"Clinical experience with inhibition of interleukin-6","volume":"30","author":"Choy","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"R8-20250722","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","article-title":"Tocilizumab in the treatment of the adult-onset Still\u2032s disease: current clinical evidence","volume":"32","author":"De Boysson","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R9-20250722","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in refractory adult-onset still\u2032s disease: multicenter retrospective open-label study of 34 patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheum"},{"key":"R10-20250722","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/art.10620","article-title":"Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still\u2032s disease","volume":"46","author":"Iwamoto","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R11-20250722","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/08830185.2014.938325","article-title":"Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights","volume":"34","author":"Hashizume","year":"2015","journal-title":"Int Rev Immunol"},{"key":"R12-20250722","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of toeilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R13-20250722","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still's disease","volume":"18","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"R14-20250722","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-011-1917-9","article-title":"Successful treatment of adult-onset Still\u2032 s disease with tocilizumab monotherapy: two case reports and literature review","volume":"31","author":"Sakai","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R15-20250722","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1756-185X.12324","article-title":"A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still\u2032s disease: targeting IL-6","volume":"17","author":"Kadavath","year":"2014","journal-title":"Int J Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201908090-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:00:47Z","timestamp":1753200047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201908090-00028"}},"subtitle":["A STROBE-compliant article"],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":15,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016682","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}